Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Longeveron Begins Enrollment of Second Cohort of Phase 1 Alzheimer’s Disease Trial

May 10, 2017 By Cade Hildreth, Founder & President Leave a Comment

MIAMI, May 10, 2017 — Longeveron, a regenerative medicine company, announced that their Phase 1 Alzheimer’s disease trial will proceed with enrollment at the recommendation of an independent Data Monitoring Committee (DMC) which reviewed data from the trial’s safety run-in phase.

The clinical trial is designed to assess the safety, tolerability and efficacy of intravenous infusion of two different doses of Longeveron mesenchymal stem cells (LMSCs) compared to placebo. The DMC reviewed safety data from a five-patient run-in phase where subjects diagnosed with Alzheimer’s disease were given a single infusion of either LMSCs or placebo. Longeveron now has the green light to continue the trial.

[Read more…]

RoosterBio Launches Xeno-Free hMSC Cell Banks to Advance Stem Cell Biomanufacturing

May 4, 2017 By Cade Hildreth, Founder & President Leave a Comment

RoosterBio Launches the Regenerative Medicine Industry’s First Xeno-Free hMSC Cell Banks to Advance and Simplify Stem Cell Biomanufacturing

FREDERICK, MARYLAND, May 04, 2017–At a CAGR of 23.2% and estimated revenue of $68B by 2020, the Regenerative Medicine (“RM”) industry continues to call for new tools designed to accelerate this aggressive growth. Based on strong RM market demand, RoosterBio Inc today announces the launch of xeno-free (“XF”) human bone-marrow derived mesenchymal stem/stromal cell (hMSC) products.

[Read more…]

Governments on Alert and Stockpiling Antidotes for Nuclear Accidents and Attacks

May 2, 2017 By Cade Hildreth, Founder & President Leave a Comment

Many governments, including the U.S. and Japan, are well aware of the dangers to their populations of exposure to high levels of radiation from nuclear accidents or dirty bomb attacks. Whereas Japan’s population was recently exposed at Fukushima following the tsunami of 2011, the U.S. Department of Defense has been stockpiling acute radiation syndrome (ARS) countermeasures as a precaution for many years.

The recent escalation of tensions between North Korea and the U.S. may give the American government cause to up its investment in ARS antidotes. During a military parade on April 15^th, North Korea displayed weapons including an intercontinental ballistic missile (ICBM) that could be capable of reaching the U.S. ARS may have just become a larger threat to health than it was just a few weeks ago. [Read more…]

Cynata Ramping Up Asthma Program

April 4, 2017 By Cade Hildreth, Founder & President Leave a Comment

Late last year, Australian stem cell and regenerative medicine company, Cynata Therapeutics Limited (ASX: CYP), developed compelling data in an asthma model and is now ramping up that program.

In October 2016, Cynata announced it had received convincing data from a proof of concept study of its Cymerus™ iPSC-derived mesenchymal stem cells (MSCs) in an experimental model of asthma. Those initial results demonstrated that Cymerus™ MSCs can exert a powerful effect via improved airway hyper-responsiveness. [Read more…]

Cynata Therapeutics Lands Japanese Giant Fujifilm

March 28, 2017 By Cade Hildreth, Founder & President Leave a Comment

It is not every day that an Aussie minnow lands a deal with a Japanese whale. When Fujifilm took a 9% equity stake in Cynata Therapeutics Ltd (ASX: CYP), it was a major lift for the regenerative medicine company, positioning Cynata to benefit not only from Fujifilm’s resources but also more broadly from current economic strategy within Japan.

Prime Minister of Japan, Shinzō Abe, has committed to building leadership around a new generation of regenerative medicine products involving human cells and tissues and Cynata is now perfectly positioned to take advantage of this in the world’s second largest market for healthcare products. [Read more…]